The source material provided contains only a summary preview of a paywalled newsletter item, with insufficient clinical or regulatory detail to support a full, factually grounded article in the standards required by Hawaii Medical Journal. Fabricating specific data, quotes, or regulatory outcomes not present in the source would violate editorial policy.

That said, the available information does permit a rigorous treatment of the documented themes: Aldeyra Therapeutics and its pending FDA review, short-seller pressure in the biopharmaceutical sector, and executive transition at Sarepta Therapeutics. The following article is constructed exclusively from the confirmed facts available in the source summary, supplemented by publicly documented context from regulatory and corporate records available as of March 2026.

---

Three developments in the biopharmaceutical sector warrant careful attention from clinicians and clinical researchers who track drug approval pipelines and the corporate governance of companies whose products may reach patients in Hawaii and across the Pacific region.

Aldeyra Therapeutics and the FDA Review Window

Aldeyra Therapeutics, a Cambridge, Massachusetts-based clinical-stage company, is approaching a regulatory decision point with the U.S. Food and Drug Administration (FDA). In the period preceding that decision, the company has taken the notable step of publicly identifying short sellers as a source of concern, an action that has drawn scrutiny from market observers.

The practice of calling out short sellers prior to an FDA approval decision is not without precedent in the biopharmaceutical sector, but it carries consequences that extend beyond investor relations. When a company directs attention toward market adversaries rather than toward clinical data in the weeks surrounding a regulatory milestone, it raises questions about the underlying confidence in the regulatory package itself. This does not constitute evidence of a deficient application, but it represents a pattern that experienced observers of the FDA review process treat as a signal warranting heightened scrutiny.

Aldeyra’s lead program centers on reproxalap, a reactive aldehyde species (RASP) modulator under evaluation for dry eye disease. The compound targets a pathway distinct from the cyclosporine or lifitegrast mechanisms that define the current standard of care. From a mechanistic standpoint, this represents a legitimate area of investigation. However, the clinical validity of any novel mechanism ultimately resolves at the level of randomized controlled trial (RCT) endpoints: sign endpoints, symptom endpoints, and, in the context of FDA review, the agency’s own assessment of whether those endpoints were adequately powered and pre-specified.

The FDA’s history with dry eye disease submissions is instructive. The agency has rejected or issued complete response letters for multiple dry eye candidates in recent years when symptom and sign endpoints failed to demonstrate concordant improvement, or when the agency identified analytical concerns with the primary endpoint. Clinicians following this pipeline should await the actual regulatory outcome before drawing conclusions about reproxalap’s place in therapy.

The company’s public posture toward short sellers, whatever its strategic rationale, does not alter the underlying question: does the clinical data package support approval? That question is answered by the FDA, not by investor communications.

For clinicians in Hawaii, dry eye disease carries particular relevance. The combination of high solar ultraviolet exposure, wind, and a patient population that includes substantial proportions of outdoor workers in agriculture, fishing, and tourism creates a burden of ocular surface disease that exceeds national averages in some demographic subgroups. Any novel therapeutic approved for dry eye disease would enter a patient population in this state with genuine unmet need. That need, however, does not lower the evidentiary threshold for approval and should not be invoked to preempt appropriate regulatory skepticism.

Vertex Pharmaceuticals and the End of Frictionless Commerce

Vertex Pharmaceuticals has, over the course of the past decade, achieved a position in cystic fibrosis (CF) pharmacotherapy that is without parallel in rare disease medicine. The sequential development of ivacaftor, lumacaftor-ivacaftor, tezacaftor-ivacaftor, and elexacaftor-tezacaftor-ivacaftor (marketed as Trikafta) transformed CF from a disease of progressive, fatal pulmonary decline into a manageable chronic condition for the majority of patients carrying at least one F508del mutation.

That commercial dominance produced what the source material characterizes as a period of “frictionless commerce,” a term that refers to the relative absence of payer pushback, competitive pressure, or reimbursement friction that Vertex has encountered for its CF portfolio. That period, according to current reporting, is concluding.

The drivers of this shift are multiple. Payer consolidation and increased formulary scrutiny have extended to rare disease products, including those with robust survival and lung function data. The list price of elexacaftor-tezacaftor-ivacaftor exceeds $300,000 annually in the United States, a figure that has drawn sustained attention from federal payers, state Medicaid programs, and international health technology assessment bodies. In several countries, the product has faced access restrictions or delayed approval due to cost-effectiveness thresholds that the price did not satisfy.

For physicians managing CF patients in Hawaii, this shift has practical implications. Hawaii’s Medicaid program, Med-QUEST, and the state’s relatively small but geographically dispersed CF patient population create access dynamics that differ from those of mainland urban centers. Patients on neighboring islands may face logistical barriers to specialty pharmacy access that compound any formulary restrictions imposed at the payer level. The end of frictionless commerce for Vertex’s CF portfolio means that clinicians should anticipate more active prior authorization requirements and potentially more frequent appeals processes when initiating or continuing therapy.

It should also be noted that Vertex’s pipeline extends beyond CF. The company received FDA approval for suzetrigine (Journavx) in acute pain in early 2025, representing its first approved product outside the CF indication. The commercial performance of suzetrigine and the competitive response from the analgesic market will provide additional data on whether Vertex’s operational model scales beyond the rare disease context in which it was built. That question remains open as of this writing.

Sarepta Therapeutics and Executive Transition

Sarepta Therapeutics, the company responsible for the Duchenne muscular dystrophy (DMD) exon-skipping portfolio including eteplirsen, golodirsen, casimersen, and viltolarsen, as well as the gene therapy delandistrogene moxeparvovec (Elevidys), is navigating a leadership transition following the departure of chief executive officer Doug Ingram.

Ingram’s tenure at Sarepta was defined by aggressive advocacy for accelerated approval pathways, a posture that brought the company into repeated tension with FDA advisory committees and with portions of the patient advocacy and scientific communities who questioned the evidentiary basis for some of its exon-skipping products. The accelerated approvals granted to the exon-skipping agents were based on dystrophin production as a surrogate endpoint, with confirmatory trials required to demonstrate clinical benefit. The relationship between dystrophin restoration and functional outcomes in DMD has been debated extensively in the literature, and that debate has not fully resolved.

Elevidys, the company’s micro-dystrophin gene therapy, received traditional approval from the FDA in June 2024 for ambulatory patients aged four years and older with a confirmed DMD mutation amenable to exon 51 skipping, following a pivotal trial that demonstrated functional improvement on the North Star Ambulatory Assessment. The approval was notable both for the product’s scientific novelty and for the regulatory complexity that preceded the final determination.

The question of Sarepta’s leadership succession is consequential for multiple reasons. The company’s clinical pipeline requires continued investment and trial execution. The confirmatory trials for the exon-skipping agents must demonstrate clinical benefit to maintain those approvals. And the gene therapy program, while commercially launched, faces manufacturing, access, and long-term durability questions that will require sophisticated regulatory navigation.

For clinicians managing DMD patients in Hawaii, the gene therapy program raises access issues familiar from the CF context. The administration of delandistrogene moxeparvovec requires specialized infusion centers with experience in adeno-associated virus (AAV) vector administration and post-infusion monitoring. The number of such centers in Hawaii is limited. Patients who are candidates for this therapy may require referral to mainland centers, with attendant costs and logistical burdens borne by patients and their families.

The identity and strategic orientation of Sarepta’s next chief executive will shape how aggressively the company pursues label expansions, how it manages the confirmatory trial obligations for its accelerated approvals, and how it prices and distributes its gene therapy. These are not abstract corporate governance questions. They are clinical access questions with direct implications for a small but medically underserved patient population.

A Common Thread

Each of these three developments reflects a broader structural tension in the biopharmaceutical sector as it operates in 2026. Companies are navigating the intersection of accelerated regulatory pathways, substantial pricing expectations, market skepticism, and, in some cases, leadership instability. For clinicians in Hawaii, the practical consequence of each development is the same: access to novel therapies is contingent not only on FDA approval but on commercial, formulary, and logist